trending Market Intelligence /marketintelligence/en/news-insights/trending/TaLpmnpTRij_5Xia_a0Trg2 content esgSubNav
In This List

Aclaris Therapeutics plans common stock offering

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Aclaris Therapeutics plans common stock offering

Aclaris Therapeutics Inc. plans to sell its common shares in an underwritten public offering.

The company also plans to grant the underwriters an option to buy up to an additional 15% of the common shares in the offering.

Leerink Partners and Evercore ISI are acting as joint book-running managers for the offering.

The Wayne, Pa.-based biopharmaceutical company develops therapies for medical and aesthetic dermatology and immunology in the U.S.